SS Innovations International (SSII) 10-Q 30 Jun 22 2020 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2020	Jun. 29, 2022
Document Information Line Items
Entity Registrant Name	AVRA MEDICAL ROBOTICS, INC.
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		37,808,805
Amendment Flag	false
Entity Central Index Key	0001676163
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Mar. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q1
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	333-216054
Entity Incorporation, State or Country Code	FL
Entity Tax Identification Number	47-3478854
Entity Address, Address Line One	3259 Progress Drive
Entity Address, Address Line Two	Suite 112A
Entity Address, City or Town	Orlando
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	32826
City Area Code	(407)
Local Phone Number	956-2250
Entity Interactive Data Current	No

Condensed Balance Sheets (Unaud

Condensed Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2020	Dec. 31, 2019
CURRENT ASSETS:
Cash and cash equivalents	$ 10,120	$ 28,474
Other prepaid expenses and deposit	2,290	6,290
Total Current Assets	12,410	34,764
EQUIPMENT:
Equipment	98,592	119,592
Accumulated depreciation	(41,312)	(34,954)
Total Equipment, net	57,280	84,638
OTHER ASSETS:
Website	36,122	36,122
Accumulated amortization	(26,000)	(23,000)
Total Other Assets, net	10,122	13,122
TOTAL ASSETS	79,812	132,524
CURRENT LIABILITIES:
Accounts payable	116,389	141,417
Accrued compensation
Accrued expenses	661,251	596,865
Notes payable - related party	368,500	367,500
Promissory notes	25,000	90,000
Total Current Liabilities	1,171,140	1,195,782
Commitments and contingencies (see Note 8)
STOCKHOLDERS’ DEFICIT:
Preferred stock, 5,000,000 shares authorized, $.0001 par value, none issued or outstanding
Common stock to be issued, _ and _ shares, $.0001 par value at March 31, 2020 and December 31, 2019 , respectively
Common stock, 100,000,000 shares authorized, $.0001 par value, 22,992,752 and 21,857,218 issued and outstanding at March 31, 2020 and December 31, 2019 respectively	2,299	2,186
Common stock liability, 83,626 and 128,909 shares, $.0001 par value at March 31, 2020 and December 31, 2019, respectively	83,626	254,564
Additional paid-in capital	4,998,828	4,549,058
Accumulated Deficit	(6,176,081)	(5,869,066)
Total Stockholders’ Deficit	(1,091,328)	(1,063,258)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$ 79,812	$ 132,524

Condensed Balance Sheets (Una_2

Condensed Balance Sheets (Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	22,992,752	21,857,218
Common stock, shares outstanding	22,992,752	21,857,218
Common stock liability, Common stock to be issued	83,626	128,909
Common stock liability common stock par value (in Dollars per share)	$ 0.0001	$ 0.0001

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Statement [Abstract]
Revenues
OPERATING EXPENSES
Research and Development	2,000	24,062
Compensation Expense
General and Administrative	304,671	370,267
Total Operating Expenses	306,671	394,329
OTHER INCOME AND (EXPENSES)
Interest Earned		3
Interest Expense	(344)	(1,155)
Total Other Income and (Expenses), net	(344)	(1,152)
Loss before Income Taxes	(307,015)	(395,481)
Provision for Income Taxes
NET LOSS	$ (307,015)	$ (395,481)
Loss per common share - basic and diluted (in Dollars per share)	$ (0.01)	$ (0.02)
- basic and diluted (in Shares)	22,976,445	21,118,618

Condensed Statement of Stockhol

Condensed Statement of Stockholders’ (Deficit) (Unaudited) - USD ($)	Common Stock	Common Stock to be Issued	Additional Paid-In Capital	Accumulated Deficit	Total
Balance as of beginning at Dec. 31, 2018	$ 2,101	$ 81,312	$ 2,176,643	$ (2,483,093)	$ (223,037)
Balance as of beginning (in Shares) at Dec. 31, 2018	21,007,446	65,050
Stock based compensation expense			48,372		48,372
Stock issued for services	$ 11		143,801		143,812
Stock issued for services (in Shares)	115,050
Common stock issuable for services		$ 23,202			23,202
Common stock issuable for services (in Shares)		170,556
Net loss				(395,481)	(395,481)
Balance as of ending at Mar. 31, 2019	$ 2,112	$ 104,514	2,385,037	(2,878,574)	(386,911)
Balance as of ending (in Shares) at Mar. 31, 2019	21,122,496	235,606
Stock warrants			16,221		16,221
Balance as of beginning at Dec. 31, 2019	$ 2,186	$ 254,564	4,549,038	(5,869,066)	(1,063,278)
Balance as of beginning (in Shares) at Dec. 31, 2019	21,857,218	128,909
Stock based compensation expense			126,059		126,059
Conversion of debt to equity	$ 101		119,899		120,000
Conversion of debt to equity (in Shares)	1,013,334
Stock issued for services	$ 12		203,832		203,844
Stock issued for services (in Shares)	122,200
Common stock issuable for services		$ (170,938)			$ (170,938)
Common stock issuable for services (in Shares)		(13,901)			122,200
Net loss				(307,015)	$ (307,015)
Balance as of ending at Mar. 31, 2020	$ 2,299	$ 83,626	$ 4,998,828	$ (6,176,081)	$ (1,091,328)
Balance as of ending (in Shares) at Mar. 31, 2020	22,992,752	115,008

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss	$ (307,015)	$ (395,481)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	9,358	6,514
Stock compensation expense	178,945	131,887
Non-cash interest		901
Changes in operating assets and liabilities:
Prepaid expenses	4,000
Accounts payable and accrued expenses	64,358	148,493
Net Cash Used in Operating Activities	(50,354)	(107,686)
INVESTING ACTIVITIES:
Equipment acquisition	(4,000)
Net Cash Used in Investing Activities	(4,000)
FINANCING ACTIVITIES:
Proceeds from exercise of stock options		21,000
Proceeds from related party	101,000	17,500
Proceeds from promissory notes	(65,000)	95,000
Net Cash Provided by Financing Activities	36,000	133,500
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(18,354)	25,814
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD	28,474	35,716
CASH AND CASH EQUIVALENTS - END OF PERIOD	10,120	61,530
Non-cash investing activities:
Cash paid for interest	344	254
Cash paid for income taxes
Non-cash financing activities:
Equipment acquisition included in accounts payable
Related party note payable converted into common stock	100,000
Promissory note converted into common stock	20,000
Reduction of account payable and equipment	$ 25,000

Company and Basis of Presentati

Company and Basis of Presentation	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
COMPANY AND BASIS OF PRESENTATION	NOTE 1 – COMPANY AND BASIS OF PRESENTATION Organization AVRA Medical Robotics, Inc. (the “Company” or “AVRA”) was incorporated as AVRA Surgical Microsystems, Inc. in the State of Florida on February 4, 2015. Effective November 5, 2015, the Company’s corporate name was changed to AVRA Medical Robotics, Inc. The Company was established to develop advanced medical surgical devices. The Company is structured to invest in four principal areas – surgical robotic systems, surgical tools, implantable devices and surgical robotic training. The significant accounting policies of AVRA were described in Note 1 to the audited financial statements included in the Company’s 2019 Annual Report on Form 10-K (“2019 Form 10-K”). There have been no significant changes in the Company’s significant accounting policies for the three months ended March 31, 2020. Basis of Presentation The accompanying unaudited condensed financial statements of the Company have been prepared in conformity with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and in accordance with the rules and regulations of the Securities and Exchange Commission. Therefore, they do not include all information and footnotes normally included in annual consolidated financial statements and should be read in conjunction with the consolidated financial statements and notes thereto included in the 2019 Form 10-K for the year ended December 31, 2019. In the opinion of the Company’s management, the accompanying unaudited condensed financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of March 31, 2020 and the results of operations and cash flows for the periods presented. The results of operations for the three months ended March 31, 2020 are not necessarily indicative of the operating results for the full fiscal year or any future period. Going Concern The accompanying financial statements have been prepared assuming the continuation of the Company as a going concern. At March 31, 2020, the Company’s stockholders’ deficit was $1,091,328 which raises substantial doubt about the Company. The Company has not yet established an ongoing source of revenues sufficient to cover its operating costs and is dependent on debt and equity financing to fund its operations. Management of the Company is making efforts to raise additional funding until a registration statement relating to an equity funding facility is in effect. While management of the Company believes that it will be successful in its capital formation and planned operating activities, there can be no assurance that the Company will be able to raise additional equity capital, or be successful in the development and commercialization of the products it develops or initiates collaboration agreements thereon. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses. The Company regularly evaluates estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates made by management. Cash and Cash Equivalents The Company considers all cash on hand, cash accounts not subject to withdrawal restrictions or penalties, and all highly liquid debt instruments purchased with a maturity of three months or less to be cash and cash equivalents. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. The Company maintains its principal cash balance in a financial institution. These balances are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At March 31, 2020 and 2019, $0 were in excess of the FDIC insured limit. Revenue Recognition In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606). The ASU and all subsequently issued clarifying ASUs replaced most existing revenue recognition guidance in U.S. GAAP. The ASU also required expanded disclosures relating to the nature amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The Company adopted the new standard effective January 1, 2018, the first day of the Company’s fiscal year. For these reasons, the adoption of this ASU did not have a significant impact on the Company’s financial statements Effective January 1, 2018, the Company adopted guidance issued by the FASB regarding recognizing revenue from contracts with customers. The revenue recognition policies as enumerated below reflect the Company’s accounting policies effective January 1, 2018, which did not have a materially different financial statement result than what the results would have been under the previous accounting policies for revenue recognition. Equipment Equipment is recorded at cost and depreciated using the straight-line method at rates determined to estimate the useful lives of the assets. The annual rates used in calculating depreciation is as follows: Equipment -5 years straight-line Intangibles Intangible assets continue to be subject to amortization, and any impairment is determined in accordance with ASC 360, “Property, Plant, and Equipment,” intangible assets are stated at historical cost and amortized over their estimated useful lives. The Company uses a straight-line method of amortization, unless a method that better reflects the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up can be reliably determined The Company purchased existing Intellectual Property from the University of Central Florida. Management regularly assesses the carrying value of the intellectual property to determine if there has been any diminution of value. Website Website is recorded at cost and amortized using the straight-line method over its estimated life of 3 years. Long-lived Assets In accordance with ASC 360, “ Property Plant and Equipment Stock Compensation Expense The Company accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance with Accounting Standards Codification (“ASC”) Topic 505, “Equity.” Costs are measured at the estimated fair market value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The value of equity instruments issued for consideration other than employee services is determined on the earlier of a performance commitment or completion of performance by the provider of goods or services as defined by ASC Topic 505. Income Taxes The Company accounts for income taxes pursuant to ASC Topic 740 “ Income Taxes. The Company applies the provisions of ASC Topic 740-10-05 “ Accounting for Uncertainty in Income Taxes Basic and Diluted Loss per Share In accordance with ASC Topic 260 “ Earnings Per Share, Research and Development Costs In accordance with ASC Topic 730 “Research and Development”, with the exception of intellectual property that is purchased from another enterprise and have alternative future use, research and development expenses are charged to operations as incurred. Fair Value of Financial Instruments Our financial instruments consist principally of accounts receivable, amounts due to related parties and promissory notes payable. The carrying amounts of cash and cash equivalents and promissory notes approximate fair value because of the short-term nature of these items. Recent Accounting Pronouncements Compensation—Stock Compensation In May 2017, the FASB issued ASU 2017-09, “Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting,” that provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. The new guidance became effective for the Company on January 1, 2018 and was applied on a prospective basis, as required. The adoption of this standard did not have an impact on the financial statements or the related disclosures. Leases In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). The FASB issued ASU 2016-02 to increase transparency and comparability among organizations recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Under ASU 2016-02, lessors will account for leases using an approach that is substantially equivalent to existing GAAP for sales-type leases, direct financing leases and operating leases. Unlike current guidance, however, a lease with collectability uncertainties may be classified as a sales-type lease. If collectability of lease payments, plus any amount necessary to satisfy a lessee residual value guarantee, is not probable, lease payments received will be recognized as a deposit liability and the underlying assets will not be derecognized until collectability of the remaining amounts becomes probable. ASU 2016-02 is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted, and must be adopted using a modified retrospective transition. The Company did not adopt the standard effective January 1, 2019, utilizing the lessor practical expedient. On November 15, 2019, the FASB issued ASU 2019-10 which amended the effective dates for ASC 842, to give implementation relief. Under the FASB’s new framework, two “buckets” were defined, bucket 1 includes public companies that are SEC filers but excludes “Small Reporting Companies” (SRC’s). Bucket 2 includes all other entities, including SRC’s. Bucket 2 entities have to apply ASC 842 for fiscal years beginning after December 15, 2020, and interim periods within fiscal years beginning after December 15, 2021.

Notes Payable _ Related Party

Notes Payable – Related Party	3 Months Ended
	Mar. 31, 2020
Related Party Transactions [Abstract]
NOTES PAYABLE – RELATED PARTY	NOTE 3 – NOTES PAYABLE – RELATED PARTY On December 31, 2018, the Company borrowed $15,000 under a non-interest bearing promissory note from a related party. The note matured on December 31, 2019 and was extended to December 31, 2020. On February 6, 2019, the Company borrowed from its CEO, $17,500 under a non-interest bearing promissory note which matures on February 6, 2020 and was extended to December 31, 2020. On May 8, 2019, the Company borrowed from its CEO, $25,000 under a non-interest bearing promissory note which matures on May 8, 2020 and was extended to December 31, 2020. On May 29, 2019, the Company borrowed from its CEO, $25,000 under a non-interest bearing promissory note which matures on May 29, 2020 and was extended to December 31, 2020. On June 26, 2019, the Company borrowed from its CEO, $40,000 under a non-interest bearing promissory note which matures on June 26, 2020 and was extended to December 31, 2020. On July 19, 2019, the Company borrowed from its CEO, $50,000 under a non-interest bearing promissory note which matures on July 19, 2020 and was extended to December 31, 2020. On October 11, 2019, the Company borrowed from its CEO, $30,000 under a non-interest bearing promissory note which matures on March 11, 2020 and was extended to December 31, 2020. On November 14, 2019, the Company borrowed from its CEO, $7,000 under a non-interest bearing promissory note which matures on November 14, 2020 and was extended to December 31, 2020. On March 1, 2020, the Company entered into a promissory notes totaling $194,500 for the above notes, as an incentive to its CEO for entering into this agreement, issued option to purchase 389,000 restricted common shares of the Company at $0.25 per share. The option will be fully vested as of March 1, 2020. On August 26, 2019, the Company borrowed from its CEO, $100,000 under a non-interest bearing promissory note which matures on December 26, 2019. On December 3, 2019, the Company borrowed from its CEO, $3,000 under a non-interest bearing promissory note which matures on December 3, 2020. On December 6, 2019, the Company borrowed from its CEO, $30,000 under a non-interest bearing promissory note which matures on December 6, 2020. On December 30, 2019, the Company borrowed from its CEO, $25,000 under a non-interest bearing promissory note which matures on December 30, 2020. On January 3, 2020, the Company borrowed from its CEO, $95,000 under a non-interest bearing promissory note which matures on January 3, 2021. On January 5, 2020, the related party exercised his option and converted his note of $100,000 into 1,000,000 shares at $0.10 per share. On March 31, 2020, the Company borrowed from its CEO, $6,000 under a non-interest bearing promissory note which matures on December 31, 2020.

Promissory Notes

Promissory Notes	3 Months Ended
	Mar. 31, 2020
Promissory Notes [Abstract]
PROMISSORY NOTES	NOTE 4 – PROMISSORY NOTES On December 31, 2018, the Company borrowed an additional $15,000, with interest payable annually at 4%, maturing on December 31, 2019. This note was paid in full on January 7, 2020. During January 2019, the Company borrowed $20,000 under a non-interest bearing promissory note which matures on December 31, 2019, this amount was converted to 13,334 shares of common stock in 2020. On March 11, 2019, the Company borrowed $25,000 under a promissory note bearing an annual interest rate of 5% and which matures on September 11, 2019. The loan includes a warrant to purchase 12,500 common shares at a strike price of $1.25 per share. The warrant expires in 3 years. This note was paid in full on January 16, 2020. On March 14, 2019, the Company borrowed $25,000 under a promissory note bearing an annual interest rate of 5% and which matures on September 14, 2019 and was extended until December 31, 2020. The loan includes a warrant to purchase 12,500 common shares at a strike price of $1.25 per share. The warrant expires in 3 years. On March 29, 2019, the Company borrowed $25,000 under a promissory note bearing an annual interest rate of 5% and which matures on September 29, 2019. The loan includes a warrant to purchase 12,500 common shares at a strike price of $1.25 per share. The warrant expires in 3 years. This note was paid in full on January 21, 2020. During the three months ended March 31, 2020, 37,500 warrants were valued at $51,740 and expensed as stock compensation.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2020
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 5– INCOME TAXES The Company’s deferred tax assets at March 31, 2020 consist of net operating loss carry forwards of $3,329,457 Using a new federal statutory tax rate of 21%, the valuation allowance balance as of March 31, 2019 total of $699,186. The increase in the valuation allowance balance for the three months ended March 31, 2020 of $26,615 is entirely attributable to the net operating loss. Due to the uncertainty of their realization, no income tax benefits have been recorded by the Company for these loss carry forwards as valuation allowances have been established for any such benefits. The increase in the valuation allowance was the result of increases in the net operating losses discussed above. Therefore, the Company’s provision for income taxes is $-0- for the three months ended March 31, 2020 and 2019. At March 31, 2020 and December 31, 2019, the Company had no material unrecognized tax benefits and no adjustments to liabilities or operations were required. The Company does not expect that its unrecognized tax benefits will materially increase within the next twelve months. The Company recognizes interest and penalties related to uncertain tax positions in general and administrative expense. At March 31, 2020 and December 31, 2019, the Company has not recorded any provisions for accrued interest and penalties related to uncertain tax positions. The Company files U.S. federal and state income tax returns in jurisdictions with varying statutes of limitations.

Stockholders' Deficit

Stockholders' Deficit	3 Months Ended
	Mar. 31, 2020
Stockholders' Equity Note [Abstract]
STOCKHOLDERS’ DEFICIT	NOTE 6 – STOCKHOLDERS’ DEFICIT The Company is authorized to issue up to 100,000,000 shares of common stock, $0.0001 par value per share plus 5,000,000 shares of preferred stock, par value $0.0001. On February 1, 2016 subscriptions were issued for 5,899,600 shares of common stock at $0.0001 per share (total $590). In February 2017, the Company raised an additional $135,000 from a private offering of 135,000 shares of common stock at a price of $1.00 per share made to three investors. On September 30, 2017, the Company raised an additional $542,260, from a private offering of 433,808 shares of common stock at a price of $1.25 per share. Effective April 1, 2017, the Company entered into Conversion Agreements with its Chairman/CEO and the Chief Financial Officer whereby each agreed to convert the amounts owing to them as of March 31, 2017 as compensation into common stock of the Company at a price of $2.00 per share. Furthermore, the Chief Financial Officer has agreed to convert any future amounts due as compensation per his Employment Agreement effective through August 1, 2017, into shares of common stock at $2.00 per share as such amounts are earned, and the Chairman/CEO has agreed to convert any future amounts in excess of $2,500 per month due as compensation through July 1, 2017, per his Employment Agreement, into shares of common stock at $2.00 per share as such amounts are earned. On April 1, 2017, 57,438 shares were issued under the agreement to convert compensation due to the Chairman/CEO and Chief Financial Officer. Both agreements were renewed upon their respective expirations. As of July 1, 2017, the Chairman/CEO agreed to convert any future amounts in excess of $2,500 per month due as compensation through December 31, 2017, per his Employment Agreement, into shares of common stock at $2.00 per share, as such amounts are earned. As of August 1, 2017, the Chief Financial Officer agreed to convert all cash payments due to the employee per his Employment Agreement, into shares of common stock using a price of $2.00 per share, as such amounts are earned. On September 30, 2017, the Chairman/CEO and the Chief Financial Officer converted $117,000 of compensation owed into 58,500 common shares. In addition, on September 30, 2017, the promissory notes of $480,000 were converted into 960,000 shares of common stock (see Note 5). The interest due on the promissory note was exchanged for Warrants to purchase 144,000 common shares at $1.25. The Warrants expire on the third-year anniversary. On February 23, 2018, the board of directors of AVRA authorized the issuance of an aggregate of 218,000 shares of AVRA’s common stock (the “Shares”) as follows: ● 150,000 Shares at a value of $1.25 per Share, to six consultants and service providers for services rendered through December 31, 2017; ● 35,000 Shares, at a value of $1.25 per Share, to Farhan Taghizadeh, M.D., AVRA’s Chief Medical Officer, for services rendered during the period September 1, 2017 to December 31, 2017; and ● 19,500 and 13,500 Shares, at a value of $2.00 per Share, to Barry F. Cohen and A. Christian Schauer, our Chief Executive Officer and its former Chief Financial Officer, respectively, pursuant to Conversion Agreements with each of such officers, under which they converted all December 31, 2017 accrued but unpaid compensation due them under their respective employment agreements with the Company into the Shares. On August 13, 2018 the Company sold 16,000 shares of its common stock for $20,000. On October 4, 2018, the Board of Directors adopted the following resolutions and took the following actions by unanimous written consent in lieu of a meeting in accordance with the applicable provisions of the Florida business Corporation Act: ● 128,300 shares of restricted common stock required to be issued, to six consultants and service providers for services rendered through September 30, 2018; ● 400 shares of restricted common stock required to be issued, for services rendered through February 28, 2018; On January 4, 2019, 115,050 Shares at a value of $1.25 per share were issued for service rendered. On April 1, 2019, 95,050 shares at a value ranging from $1.25-$2.41 per share were issued for services rendered. On July 1, 2019, 79,672 shares at a value ranging from $1.25-$2.76 per share were issued for services rendered. On August 28, 2019, 600,000 shares at a value ranging from $1.25-$2.00 per share were issued for services rendered. On December 1, 2019, the Company canceled 250,000 restricted shares of the Company’s common stock that were previously issued to you under the Stock Award letter dated August 28, 2019. During the first quarter 2020, 122,200 shares at a value ranging from $.42-$2.79 per share were issued for services rendered. Holders are entitled to one vote for each share of common stock. No preferred stock has been issued.

2016 Incentive Stock Plan

2016 Incentive Stock Plan	3 Months Ended
	Mar. 31, 2020
Disclosure Text Block Supplement [Abstract]
2016 INCENTIVE STOCK PLAN	NOTE 7 – 2016 INCENTIVE STOCK PLAN On August 1, 2016, the Company adopted the 2016 Incentive Stock Plan (the “Plan”). The Plan provides for the granting of options to employees, directors, consultants and advisors to purchase up to 3,000,000 shares of the Company’s common stock. The Board is responsible for administration of the Plan. The Board determines the term of each option, the option exercise price, the number of shares for which each option is granted and the rate at which each option is exercisable. Incentive stock options may be granted to any officer or employee at an exercise price per share of not less than the fair market value per common share on the date of the grant. On August 1, 2019, the Board increased the plan to 10,000,000 shares of common stock. For options granted October 1, 2017, the following factors were used: volatility 45.07%; expected term of 3 years, risk-free interest rate of 2.00%, dividend yield of 0% and exercise price of $1.25 per share. For options granted July 1, 2018, the following factors were used: volatility 31.34%; expected term of 3 years, risk-free interest rate of 2.00%, dividend yield of 0% and exercise price of $1.25 per share. For options granted May 1, 2018, the following factors were used: volatility 62.16%; expected term of 3 years, risk-free interest rate of 2.00%, dividend yield of 0% and exercise price of $1.25 per share. On July 1, 2018 options for 75,000 shares were issued to our Counsel for services rendered totaling $21,000. These shares are vested immediately and expire on July 1, 2023. The exercise price is $1.25. For the year ended December 31, 2019 and 2018, 210,000 and -0- options were exercised, respectively. Non-vested Options for 97,639 shares were forfeited during March 2018. On December 1, 2019, the Company granted to its majority shareholder options to purchase 750,000 common shares of the Company at an exercise price per share will be $1.00. All shares will immediately vest, and the Option will expire five years from the date of issuance. At December 31, 2019 and 2018 options representing 3,486,667 shares and 2,243,250 shares were vested or exercisable, respectively. All options issued to-date expire after five years from the issue date. Except for the option for 1,750,000 shares issued to the CEO and to the Company’s counsel for 40,000 shares that vested immediately, all the options issued to date vest over three years. Stock options are accounted for in accordance with FASB ASC Topic 718, Compensation –Stock Compensation The grant date fair value of options granted during the year of 2018 and 2019 were estimated on the grant date using the Black-Scholes model with the following assumptions: For options granted May 1, 2018, the following factors were used; volatility 62.16%; expected term of 3 years, risk-free interest rate of 2.00%, dividend yield of 0% and exercise price of $1.25 per share. For options granted July 1, 2018, the following factors were used; volatility 31.34%; expected term of 3 years, risk-free interest rate of 2.00%, dividend yield of 0% and exercise price of $1.25 per share. For options granted February 1, 2019: Volatility 50.58%, term 3 yrs, risk-free interest rate of 2.00%, dividend yield of 0% and exercise price of $2.00 per share. For options granted April 1, 2019: Volatility 48.52%, term 3 yrs, risk-free interest rate of 2.00%, dividend yield of 0% and exercise price of $1.25 per share. For options granted August 1, 2019: Volatility 62.43%, term 3 yrs, risk-free interest rate of 2.00%, dividend yield of 0% and exercise price of $2.00 per share. For options granted October 1, 2019: Volatility 48.57%, term 3 yrs, risk-free interest rate of 2.00%, dividend yield of 0% and exercise price of $2.00 per share. For options granted December 1, 2019: Volatility 61.91%, term 3 yrs, risk-free interest rate of 2.00%, dividend yield of 0% and exercise price of $1.00 per share. The grant date fair value of options granted during the year of 2020 were estimated on the grant date using the Black-Scholes model with the following assumptions: For options granted March 1, 2020 the fair market value is $0.45, exercise $0.25, rate 2%, and volatility 39.73%. Option values are calculated using Black Scholes with the following inputs: expected volatilities are based on the average volatilities of six similar companies; fair market values are calculated using the implied share values of recent company financings or OTC closing prices for that day, whichever is more suitable; risk-free rate used was 2%.

Commitments

Commitments	3 Months Ended
	Mar. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS	NOTE 8 – COMMITMENTS Intellectual property Effective May 1, 2016, the Company entered into a Research Agreement (the “Research Agreement”) with the University of Central Florida (“UCF” or the “University”) for the development of a prototype surgical robotic device supporting minimal invasive surgical facial corrections. The Agreement provides that the University will provide personnel to accomplish the objectives as stated in the Statement of Work over a period extending to September 30, 2017. Effective May 1, 2016, the research agreement with the University of Central Florida has been extended to April 30, 2021. No additional payments to the University were required. The Company agreed to extend funding of $163,307 from AVRA’s existing funds. In addition, AVRA has paid $43,548 for outright ownership of the University’s Intellectual Property resulting from the collaboration, which amount is shown as Intellectual Property. Management has assessed the carrying value of the asset at December 31, 2019 and has recorded an impairment loss in the amount of $43,548. In 2019 and 2018, $-0- had been paid under the Agreement. The balance of the amount owing to the University was fully paid on February 24, 2017 and April 7, 2017. Additionally, a $68,952 matching funds grant from the Florida High Tech Corridor Council (FHTCC) was approved on July 16, 2016 which will provide the University research funds in addition to the Company’s funding obligation to the University. The FHTCC research grant is subject to certain research obligations and action requirements which if not met may result in the loss of the FHTCC research funding. The agreement further provides for the payment of a 1% royalty to the University in any year when the sales of products using the intellectual property exceeds $20,000,000. Employment Agreements On July 1, 2016, the Company entered into an Employment Agreement with its Chairman and Chief Executive Officer. The agreement provides for an annual salary of $120,000 per year, increasing to $180,000 per year beginning July 2017. Through December 2016, the employee agreed to not receive the compensation in cash until the Board of Directors deemed it prudent to pay some or all of his salary. Further the Agreement provides that the employee will receive a three-year option to purchase 1,000,000 shares of the Company’s common stock at an exercise price of $0.10 per share, and becoming fully vested on August 15, 2016. On August 1, 2016, the Company entered into a one-year Employment Agreement with its Chief Financial Officer. The agreement provides for an annual salary of $108,000 per year. Through December 2016, the employee agreed to not receive the compensation in cash until the Board of Directors deemed it prudent to pay some or all of his salary. Further the Agreement provides that the employee will receive a three-year option to purchase 210,000 shares of the Company’s common stock at an exercise price of $0.10 per share, with 70,000 shares becoming fully vested upon each yearly anniversary. The options are to be surrendered and cancelled if the Agreement is terminated. The Agreement has expired but its compensation terms continue in effect as long as the employee remains employed by the Company. On August 1, 2016, the Company entered into a three-year Employment Agreement with its Vice President of Global Business Development. The agreement provides for an annual salary of $96,000 per year, increasing to $144,000 per year beginning July 2017. Through December 2016, the employee agreed to not receive the compensation in cash until the Board of Directors deemed it prudent to pay some or all of his salary. Further the Agreement provides that the employee will receive a three-year option to purchase 300,000 shares of the Company’s common stock at an exercise price of $0.10 per share, with 100,000 shares vested on each yearly anniversary. Further, on July 1, 2016, the Company entered into Indemnification Agreements with the Chairman and Chief Executive Officer, and on August 1, 2016 the Chief Financial Officer and the Vice-President of Global Business Development providing for the Company to indemnify the individuals for all expenses, judgments, etc. incurred while serving in various capacities with the Company. Commencing March 1, 2018, the Company entered into an employment agreement with its new Chief Strategy Officer whereby compensation will be determined upon sufficient funding of the Company. The Company granted a 300,000 share stock award under its 2016 Incentive Stock Plan, which vests in five equal annual installments of 60,000 shares each. In addition, on May 1, 2018 options for 250,000 shares that vest monthly over 3 years were also issued to our Chief Strategy Officer. These options expire on May 1, 2023 and are exercisable at $1.25. Commencing January 1, 2019, the Company entered into a consulting agreement with an IR/PR Company whereby compensation will be $1,500 per month for six months. During third quarter 2019, these services stopped. On July 1, 2019, the Company issued 36,000 restricted common shares as part of the compensation. Lease The Company occupies office and laboratory space in Orlando, Florida under a lease agreement that expired on July 31, 2018. Effective August 1, 2018 and expiring July 31, 2019, the Company signed a new agreement, with monthly payments of $1,829.25 plus applicable sales tax. Effective August 1, 2019, the Company signed a year lease agreement, provides that the Company pay insurance, maintenance and taxes with a monthly lease expense of $2,454.75 plus applicable sales tax. Effective January 15, 2020, the Company amended its August 1, 2019 lease agreement reducing its monthly lease payment to $2,223 plus applicable sales tax. Either party may cancel the agreement at any time with 30 days’ notice (see Note 15).

Other Matters

Other Matters	3 Months Ended
	Mar. 31, 2020
Other Matters [Abstract]
OTHER MATTERS	NOTE 9 – OTHER MATTERS On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the “COVID-19 outbreak”) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally. The full impact of the COVID-19 outbreak continues to evolve as of the date of this report. As such, it is uncertain as to the full magnitude that the pandemic will have on the Company’s financial condition, liquidity, and future results of operations. Management is actively monitoring the global situation on its financial condition, liquidity, operations, suppliers, industry, and workforce. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, the Company is not able to estimate the effects of the COVID-19 outbreak on its results of operations, financial condition, or liquidity for fiscal year 2020. On March 27, 2020, President Trump signed into law the “Coronavirus Aid, Relief, and Economic Security (CARES) Act.” The CARES act was enacted as a response to the COVID-19 outbreak discussed above and is meant to provide companies with economic relief. The CARES Act, among other things, includes provisions relating to refundable payroll tax credits, deferment of employer side social security payments, net operating loss carryback periods, alternative minimum tax credit refunds, modifications to the net interest deduction limitations, increased limitations on qualified charitable contributions, and technical corrections to tax depreciation methods for qualified improvement property.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2020
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 10 – SUBSEQUENT EVENTS The Company has evaluated subsequent events through the date that the financial statements were issued and determined that there were subsequent events requiring adjustments to or disclosure in the financial statements. Effective January 1, 2021, the Company signed an amendment which modified the August 1, 2020 agreement, increasing the monthly lease expense to $1,964.74 plus applicable sales tax. On October 26, 2020, AVRA issued an aggregate 256,027 Units (“Units”) at a price of $1.00 per Unit in a private offering (the “Offering”) to four “accredited investors.” Each Unit consisted of (a) four shares of our common stock (“Shares”); (b) a three-year warrant to purchase five Shares at an exercise price of $0.40 per Share; and (c) a put option of their Membership Units in Avra Air LLC for one share of our common stock. As a result of the foregoing, the investors were issued an aggregate of 1,024,108 Shares, warrants to purchase 1,280,135 Shares and put options for 256,027 Shares. One of the accredited investors, per his original commitment, subsequently invested an additional $45,000 on May 3, 2021 in this same Unit funding thus receiving an additional 180,000 Shares, a warrant to purchase 225,000 Shares and a put option for 45,000 Shares. On August 21, 2020 and October 19, 2020 the Company borrowed from its CEO, $17,700 and $11,500, respectively, under non-interest bearing promissory notes which mature on December 31, 2020 and on December 31, 2021, respectively. These were subsequently converted into shares via the purchase of Units in the following December 22, 2020 funding. On December 22, 2020 one accredited investor and the CEO invested $25,000 and $202,700, respectively, into 227,700 Units at a price of $1.00 per Unit in a private offering (the “Offering”). Each Unit consisted of (a) four shares of our common stock; and (b) a three-year warrant to purchase five Shares at an exercise price of $0.40 per Share. As a result of the foregoing, they were issued an aggregate of 910,800 Shares, and warrants to purchase 1,138,500 Shares. The CEO used a total of $202,700 of Notes due to him from the Company to purchase these Units. On January 26, 2021, AVRA issued an aggregate 235,000 Units (“Units”) at a price of $1.00 per Unit in a private offering (the “Offering”) to four “accredited investors.” Each Unit consisted of (a) four shares of our common stock (“Shares”); and (b) a three-year warrant to purchase five Shares at an exercise price of $0.40 per Share. As a result of the foregoing, the investors were issued an aggregate of 940,000 Shares, and warrants to purchase 1,175,000 Shares. On June 3, 2021, the Board of Directors ratified the following issuances of common stock: 1. The Company issued 33,000 shares of restricted common stock required to be issued for services through June 1, 2021 to Farhan Taghizadeh, per his employment agreement dated September 15, 2020. 2. The Company issued 10,000 shares of restricted common stock required to be issued to Ettore Tomassetti per his Stock Award dated April 15, 2019. 3. The Company issued 160,000 shares of restricted common stock required to be issued to Nikhil Shah per his Stock Grant Award dated April 15, 2019 and his Employment Agreement dated March 1, 2018. 4. The Company issued 5,600 shares of restricted common stock required to be issued for services through June 1, 2021 to Maria Carin Bruck, per her services agreement dated October 1, 2018. 5. The Company issued 3.889 shares of restricted common stock required to be issued for services through June 1, 2021 to Robert Santangelo, per his services agreement dated February 15, 2019. 6. The Company issued 19,445 shares of restricted common stock required to be issued for services through June 1, 2021 to Vipul Patel, per his services agreement dated September 1, 2019. 7. The Company issued 7,000 shares of restricted common stock required to be issued for services through June 1, 2021 to Henry Gewanter, per his services agreement dated February 10, 2020. 8. The Company issued 19,444 shares of restricted common stock required to be issued to Jared Stammel per his Stock Award dated September 1, 2020. 9. The Company issued 25,000 shares of restricted common stock required to be issued to Robert Chanson, per his services agreement dated February 20, 2021. 10. On October 26, 2020, the Company received a commitment to sell 135,000 units for $135,000. A $25,000 promissory note plus accrued interest of $1,027 was converted towards the commitment for 26,027 units. On May 3, 2021, the Company received $45,000 towards his commitment and the remaining balance is $63,973. The balance is due on or before October 21, 2021. (this later expired without any further payments being made) (this was also covered in paragraph above with regards to the 256,027 Units funding) In July, 2021 several holders of stock options elected to exercise their stock options with a cashless exercise provision resulting in the issuance of 629,375 shares of common stock. On September 22, 2021, the Company’s CEO, converted a total of $50,000 of notes payable into 384,615 shares of common stock and converted $50,000 of accrued salary into 384,615 shares of common stock. On October 1, 2021, the Company’s CEO, converted a total of $595,000 of accrued salary into 5,950,000 shares of common stock at a price of $0.10 per share and agreed to receive 450,000 shares of common stock for $45,000 of the remaining salary due for the three months ending December 31, 2021at a price of $0.10 per share. On October 1, 2021, a former employee now a consultant elected to convert a total of $251,500 of accrued consulting fees into 2,515,000 shares of common stock at a price of $0.10 per share, converted $161,500 of accrued salary into 1,615,000 shares of common stock at a price of $0.10 per share. and $4,500 of expenses into 45,000 shares of common stock at a price of $0.10 per share. Between October 5, 2021 and December 8, 2021 the Company sold a total of 2,229,231 shares of common stock at prices ranging between $0.13 and $0.52 per share. The Company received proceeds of $315,200. On October 1, 2021 the Company issued a total of 1,500,000 of stock options to consultants with an exercise price of $0.25 per option. On October 1, 2021 the Company issued 50,000 of stock options to each of its independent Directors with an exercise price of $0.25 per option. On October 1, 2021 the Company issued 350,000 of stock options to its Chief Medical Officer with an exercise price of $0.25 per option. On October 1, 2021 the Company issued a total of 390,000 of stock options to Company’s CEO with an exercise price of $0.25 per option for the extension of loans. On October 1, 2021 the Company issued a total of 174,553 shares of common stock to several consultants. On October 1, 2021 the Company issued 25,000 shares of common stock to its Chief Medical Officer.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	3 Months Ended
	Mar. 31, 2020
Accounting Policies [Abstract]
Estimates	Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses. The Company regularly evaluates estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates made by management.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all cash on hand, cash accounts not subject to withdrawal restrictions or penalties, and all highly liquid debt instruments purchased with a maturity of three months or less to be cash and cash equivalents.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. The Company maintains its principal cash balance in a financial institution. These balances are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At March 31, 2020 and 2019, $0 were in excess of the FDIC insured limit.
Revenue Recognition	Revenue Recognition In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606). The ASU and all subsequently issued clarifying ASUs replaced most existing revenue recognition guidance in U.S. GAAP. The ASU also required expanded disclosures relating to the nature amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The Company adopted the new standard effective January 1, 2018, the first day of the Company’s fiscal year. For these reasons, the adoption of this ASU did not have a significant impact on the Company’s financial statements Effective January 1, 2018, the Company adopted guidance issued by the FASB regarding recognizing revenue from contracts with customers. The revenue recognition policies as enumerated below reflect the Company’s accounting policies effective January 1, 2018, which did not have a materially different financial statement result than what the results would have been under the previous accounting policies for revenue recognition.
Equipment	Equipment Equipment is recorded at cost and depreciated using the straight-line method at rates determined to estimate the useful lives of the assets. The annual rates used in calculating depreciation is as follows: Equipment -5 years straight-line
Intangibles	Intangibles Intangible assets continue to be subject to amortization, and any impairment is determined in accordance with ASC 360, “Property, Plant, and Equipment,” intangible assets are stated at historical cost and amortized over their estimated useful lives. The Company uses a straight-line method of amortization, unless a method that better reflects the pattern in which the economic benefits of the intangible asset are consumed or otherwise used up can be reliably determined The Company purchased existing Intellectual Property from the University of Central Florida. Management regularly assesses the carrying value of the intellectual property to determine if there has been any diminution of value.
Website	Website Website is recorded at cost and amortized using the straight-line method over its estimated life of 3 years.
Long-lived Assets	Long-lived Assets In accordance with ASC 360, “ Property Plant and Equipment
Stock Compensation Expense	Stock Compensation Expense The Company accounts for equity instruments issued in exchange for the receipt of goods or services from other than employees in accordance with Accounting Standards Codification (“ASC”) Topic 505, “Equity.” Costs are measured at the estimated fair market value of the consideration received or the estimated fair value of the equity instruments issued, whichever is more reliably measurable. The value of equity instruments issued for consideration other than employee services is determined on the earlier of a performance commitment or completion of performance by the provider of goods or services as defined by ASC Topic 505.
Income Taxes	Income Taxes The Company accounts for income taxes pursuant to ASC Topic 740 “ Income Taxes. The Company applies the provisions of ASC Topic 740-10-05 “ Accounting for Uncertainty in Income Taxes
Basic and Diluted Loss per Share	Basic and Diluted Loss per Share In accordance with ASC Topic 260 “ Earnings Per Share,
Research and Development Costs	Research and Development Costs In accordance with ASC Topic 730 “Research and Development”, with the exception of intellectual property that is purchased from another enterprise and have alternative future use, research and development expenses are charged to operations as incurred.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Our financial instruments consist principally of accounts receivable, amounts due to related parties and promissory notes payable. The carrying amounts of cash and cash equivalents and promissory notes approximate fair value because of the short-term nature of these items.
Recent Accounting Pronouncements	Recent Accounting Pronouncements
Compensation- Stock Compensation	Compensation—Stock Compensation In May 2017, the FASB issued ASU 2017-09, “Compensation—Stock Compensation (Topic 718): Scope of Modification Accounting,” that provides guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting. The new guidance became effective for the Company on January 1, 2018 and was applied on a prospective basis, as required. The adoption of this standard did not have an impact on the financial statements or the related disclosures.
Leases	Leases In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). The FASB issued ASU 2016-02 to increase transparency and comparability among organizations recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. Under ASU 2016-02, lessors will account for leases using an approach that is substantially equivalent to existing GAAP for sales-type leases, direct financing leases and operating leases. Unlike current guidance, however, a lease with collectability uncertainties may be classified as a sales-type lease. If collectability of lease payments, plus any amount necessary to satisfy a lessee residual value guarantee, is not probable, lease payments received will be recognized as a deposit liability and the underlying assets will not be derecognized until collectability of the remaining amounts becomes probable. ASU 2016-02 is effective for interim and annual periods beginning after December 15, 2018, with early adoption permitted, and must be adopted using a modified retrospective transition. The Company did not adopt the standard effective January 1, 2019, utilizing the lessor practical expedient. On November 15, 2019, the FASB issued ASU 2019-10 which amended the effective dates for ASC 842, to give implementation relief. Under the FASB’s new framework, two “buckets” were defined, bucket 1 includes public companies that are SEC filers but excludes “Small Reporting Companies” (SRC’s). Bucket 2 includes all other entities, including SRC’s. Bucket 2 entities have to apply ASC 842 for fiscal years beginning after December 15, 2020, and interim periods within fiscal years beginning after December 15, 2021.

Company and Basis of Presenta_2

Company and Basis of Presentation (Details)	3 Months Ended
	Mar. 31, 2020 USD ($)
Accounting Policies [Abstract]
Stockholders deficit	$ 1,091,328

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
FDIC insured	$ 250,000
FDIC insured limit	$ 0	$ 0
Equipment useful life	5 years
Estimated life	3 years

Notes Payable _ Related Party (

Notes Payable – Related Party (Details) - USD ($)	Mar. 01, 2020	Jan. 05, 2020	Mar. 31, 2020	Dec. 30, 2019	Dec. 06, 2019	Dec. 03, 2019	Nov. 14, 2019	Oct. 11, 2019	Aug. 26, 2019	Jul. 19, 2019	Jun. 26, 2019	May 29, 2019	May 08, 2019	Mar. 29, 2019	Mar. 14, 2019	Mar. 11, 2019	Feb. 06, 2019	Jan. 04, 2019	Jan. 01, 2019	Dec. 31, 2018
Notes Payable – Related Party (Details) [Line Items]
Options issued to purchase restricted shares (in Shares)	389,000
Price per share (in Dollars per share)	$ 0.25	$ 0.1																$ 1.25
Stock options value exercised		$ 100,000
Stock options shares issued (in Shares)		1,000,000
Chief Executive Officer [Member]
Notes Payable – Related Party (Details) [Line Items]
Debt face amount			$ 6,000
Promissory Note [Member]
Notes Payable – Related Party (Details) [Line Items]
Debt face amount														$ 25,000	$ 25,000	$ 25,000			$ 20,000	$ 15,000
Notes payable	$ 194,500
Promissory Note [Member] | Chief Executive Officer [Member]
Notes Payable – Related Party (Details) [Line Items]
Debt face amount				$ 25,000	$ 30,000	$ 3,000	$ 7,000	$ 30,000	$ 100,000	$ 50,000	$ 40,000	$ 25,000	$ 25,000				$ 17,500

Promissory Notes (Details)

Promissory Notes (Details) - USD ($)			1 Months Ended	3 Months Ended	12 Months Ended
	Mar. 14, 2019	Mar. 11, 2019	Mar. 29, 2019	Mar. 31, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Jan. 01, 2019
Promissory Notes (Details) [Line Items]
Debt maturity date	Sep. 14, 2019	Sep. 11, 2019	Sep. 29, 2019			Dec. 31, 2019	Dec. 31, 2019
Number of warrants purchase (in Shares)	12,500			37,500
Strike price (in Dollars per share)	$ 1.25
Stock expensed compensation				$ 51,740
Promissory Note [Member]
Promissory Notes (Details) [Line Items]
Debt face amount	$ 25,000	$ 25,000	$ 25,000				$ 15,000	$ 20,000
Debt default interest rate	5%	5%	5%				4%
Common stock shares converted (in Shares)					13,334
Number of warrants purchase (in Shares)		12,500	12,500
Strike price (in Dollars per share)		$ 1.25	$ 1.25
Warrant expiration period	3 years	3 years	3 years

Income Taxes (Details)

Income Taxes (Details) - USD ($)	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Net operating loss carry forwards	$ 3,329,457
Federal statutory tax rate	21%
Federal tax benefit valuation allowance		$ 699,186
Increase valuation allowance	$ 26,615
Provision for income taxes	$ 0	$ 0

Stockholders' Deficit (Details)

Stockholders' Deficit (Details) - USD ($)

1 Months Ended

3 Months Ended

Dec. 02, 2019

Aug. 28, 2019

Jul. 02, 2019

Apr. 02, 2019

Jan. 04, 2019

Aug. 13, 2018

Feb. 28, 2018

Sep. 30, 2017

Aug. 01, 2017

Jul. 01, 2017

Apr. 01, 2017

Feb. 28, 2017

Feb. 01, 2016

Sep. 30, 2018

Feb. 23, 2018

Dec. 31, 2017

Mar. 31, 2020

Mar. 31, 2019

Dec. 22, 2020

Mar. 01, 2020

Jan. 05, 2020

Dec. 31, 2019

Stockholders' Deficit (Details) [Line Items]

Common stock, authorized shares

100,000,000

100,000,000

Common stock, par value shares

$ 0.0001

$ 0.0001

Preferred stock, authorized shares

5,000,000

5,000,000

Preferred stock, par value

$ 0.0001

$ 0.0001

Number of shares issued for subscriptions

5,899,600

Share price

$ 0.0001

Value of shares issued for subscriptions

$ 590

Share Price

$ 1.25

Debt conversion of common stock, Value

$ 480,000

Debt conversion of common stock, Shares

960,000

Number of Warrants Purchase

144,000

Aggregate of common stock

218,000

Number of common stock sold

16,000

Proceeds from sale of common stock

$ 20,000

Number of restricted common stock issued for services

400

Stock issued for services, Shares

600,000

79,672

95,050

115,050

122,200

Stock issued for services

$ 1.25

$ 0.25

$ 0.1

Restricted shares

250,000

Common Stock [Member]

Stockholders' Deficit (Details) [Line Items]

Common stock, par value shares

$ 0.0001

Stock issued for services, Shares

Common stock voting rights, description

Holders are entitled to one vote for each share of common stock.

Minimum [Member]

Stockholders' Deficit (Details) [Line Items]

Stock issued for services

$ 1.25

$ 1.25

$ 1.25

$ 0.42

Maximum [Member]

Stockholders' Deficit (Details) [Line Items]

Stock issued for services

$ 2

$ 2.76

$ 2.41

$ 2.79

Private Offering [Member]

Stockholders' Deficit (Details) [Line Items]

Value of shares issued for private offering

$ 542,260

Number of shares issued for private offering

433,808

Share Price

$ 1.25

Stock issued for services

$ 1

Chairman/CEO and the Chief Financial Officer [Member]

Stockholders' Deficit (Details) [Line Items]

Stock conversion price

$ 2

Mr. A. Christian Schauer (Chief Financial Officer) [Member]

Stockholders' Deficit (Details) [Line Items]

Stock conversion price

$ 2

Investor [Member] | Private Offering [Member]

Stockholders' Deficit (Details) [Line Items]

Value of shares issued for private offering

$ 135,000

Number of shares issued for private offering

135,000

Share Price

$ 1

Chairman CEO And Chief Financial Officer [Member]

Stockholders' Deficit (Details) [Line Items]

Debt conversion of common stock, Value

$ 117,000

Debt conversion of common stock, Shares

58,500

Six consultants and service [Member]

Stockholders' Deficit (Details) [Line Items]

Share Price

$ 1.25

Aggregate of common stock

150,000

Number of restricted common stock issued for services

128,300

Farhan Taghizadeh [Member]

Stockholders' Deficit (Details) [Line Items]

Share Price

$ 1.25

Aggregate of common stock

35,000

Mr. Barry F. Cohen (Chairman and Chief Executive Officer) [Member]

Stockholders' Deficit (Details) [Line Items]

Aggregate of common stock

19,500

Mr. A. Christian Schauer (Chief Financial Officer) [Member]

Stockholders' Deficit (Details) [Line Items]

Share Price

$ 2

Aggregate of common stock

13,500

Conversion Agreements [Member] | Chairman/CEO and the Chief Financial Officer [Member]

Stockholders' Deficit (Details) [Line Items]

Stock conversion price

$ 2

$ 2

$ 2

Monthly maximum amount convert

$ 2,500

$ 2,500

Shares issued upon compensation

57,438

2016 Incentive Stock Plan (Deta

2016 Incentive Stock Plan (Details) - USD ($)											1 Months Ended		3 Months Ended		12 Months Ended
	Mar. 01, 2020	Dec. 01, 2019	Oct. 01, 2019	Aug. 01, 2019	Apr. 01, 2019	Jul. 01, 2018	May 01, 2018	Mar. 31, 2018	Oct. 01, 2017	Jul. 01, 2017	Dec. 22, 2020	Feb. 02, 2019	Mar. 31, 2020	Mar. 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Aug. 01, 2016
2016 Incentive Stock Plan (Details) [Line Items]
Expected volatility	39.73%
Expected dividend yield							0%
Exercise price (in Dollars per share)							$ 1.25
Purchase to shareholder options (in Shares)		750,000
Exercise price per share (in Dollars per share)		$ 1									$ 0.4
Option expire		5 years
Number shares vested (in Shares)															3,486,667	2,243,250
Except option shares issued (in Shares)															1,750,000
Stock based compensation (in Dollars)													$ 178,945	$ 131,887
Unrecognized compensation cost related to non-vested options (in Dollars)															$ 291,876
Unrecognized compensation cost related to non-vested options recognized period															35 months
Fair market value per share (in Dollars per share)	$ 0.45
Exercise per share (in Dollars per share)	$ 0.25
Rate	2%
Risk-free rate													2%
2016 Incentive Stock Plan [Member]
2016 Incentive Stock Plan (Details) [Line Items]
Number of shares authorized under the plan (in Shares)				10,000,000													3,000,000
Expected volatility		61.91%	48.57%	62.43%	48.52%	31.34%	62.16%		45.07%	31.34%		50.58%
Expected term		3 years	3 years	3 years	3 years	3 years	3 years		3 years	3 years		3 years
Risk-free interest rate		2%	2%	2%	2%	2%	2%		2%	2%		2%
Expected dividend yield		0%	0%	0%	0%	0%	0%		0%	0%		0%
Exercise price (in Dollars per share)		$ 1	$ 2	$ 2	$ 1.25	$ 1.25	$ 1.25		$ 1.25	$ 1.25		$ 2
Stock issued during the period , shares (in Shares)						75,000
Stock issued during the period , value (in Dollars)						$ 21,000
Option expiration date						Jul. 01, 2023
Option exercised (in Shares)															210,000	0
Number of non-vested Options shares forfeited (in Dollars per share)								$ 97,639
Equity Option [Member]
2016 Incentive Stock Plan (Details) [Line Items]
Expected volatility							62.16%
Expected term							3 years
Risk-free interest rate							2%
Counsel for services [Member] | 2016 Incentive Stock Plan [Member]
2016 Incentive Stock Plan (Details) [Line Items]
Exercise price (in Dollars per share)						$ 1.25
Mr. Barry F. Cohen (Chairman and Chief Executive Officer) [Member]
2016 Incentive Stock Plan (Details) [Line Items]
Number shares vested (in Shares)															40,000
General and Administrative Expense [Member]
2016 Incentive Stock Plan (Details) [Line Items]
Stock based compensation (in Dollars)															$ 126,059	$ 78,372

Commitments (Details)

Commitments (Details) - USD ($)

3 Months Ended

6 Months Ended

12 Months Ended

Aug. 01, 2020

Aug. 01, 2019

Jul. 01, 2019

May 01, 2018

Mar. 01, 2018

Aug. 01, 2016

Jul. 16, 2016

Jul. 01, 2016

Mar. 31, 2020

Jun. 30, 2019

Dec. 31, 2019

Dec. 31, 2018

May 01, 2023

Jul. 31, 2019

Commitments (Details) [Line Items]

Paid under the Agreement

$ 0

$ 0

Employment agreements description

On August 1, 2016, the Company entered into a three-year Employment Agreement with its Vice President of Global Business Development. The agreement provides for an annual salary of $96,000 per year, increasing to $144,000 per year beginning July 2017. Through December 2016, the employee agreed to not receive the compensation in cash until the Board of Directors deemed it prudent to pay some or all of his salary. Further the Agreement provides that the employee will receive a three-year option to purchase 300,000 shares of the Company’s common stock at an exercise price of $0.10 per share, with 100,000 shares vested on each yearly anniversary.

Monthly lease payment

$ 2,223

Lease [Member]

Commitments (Details) [Line Items]

Sales tax

$ 1,829.25

Lease expense

$ 2,454.75

Forecast [Member]

Commitments (Details) [Line Items]

Lease expense

$ 1,964.74

Intellectual Property [Member]

Commitments (Details) [Line Items]

Extend funding value

$ 163,307

Ownership amount

$ 43,548

Impairment loss amount

$ 43,548

Research funds value

$ 68,952

Royalty rate interest

1%

Intellectual property exceeds

$ 20,000,000

Employment Agreements [Member]

Commitments (Details) [Line Items]

Shares stock award (in Shares)

300,000

Installments shares (in Shares)

60,000

Options shares vest (in Shares)

250,000

Vest date

3 years

Whereby compensation

$ 1,500

Restricted common shares (in Shares)

36,000

Employment Agreements [Member] | Forecast [Member]

Commitments (Details) [Line Items]

Options exercisable (in Dollars per share)

$ 1.25

Chief Executive Officer [Member]

Commitments (Details) [Line Items]

Employment agreements description

On July 1, 2016, the Company entered into an Employment Agreement with its Chairman and Chief Executive Officer. The agreement provides for an annual salary of $120,000 per year, increasing to $180,000 per year beginning July 2017. Through December 2016, the employee agreed to not receive the compensation in cash until the Board of Directors deemed it prudent to pay some or all of his salary. Further the Agreement provides that the employee will receive a three-year option to purchase 1,000,000 shares of the Company’s common stock at an exercise price of $0.10 per share, and becoming fully vested on August 15, 2016.

Chief Financial Officer [Member]

Commitments (Details) [Line Items]

Employment agreements description

On August 1, 2016, the Company entered into a one-year Employment Agreement with its Chief Financial Officer. The agreement provides for an annual salary of $108,000 per year. Through December 2016, the employee agreed to not receive the compensation in cash until the Board of Directors deemed it prudent to pay some or all of his salary. Further the Agreement provides that the employee will receive a three-year option to purchase 210,000 shares of the Company’s common stock at an exercise price of $0.10 per share, with 70,000 shares becoming fully vested upon each yearly anniversary. The options are to be surrendered and cancelled if the Agreement is terminated. The Agreement has expired but its compensation terms continue in effect as long as the employee remains employed by the Company.

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)

1 Months Ended

3 Months Ended

Oct. 01, 2021

Nov. 06, 2020

Aug. 01, 2020

Jul. 01, 2020

Mar. 01, 2020

Jan. 05, 2020

Dec. 01, 2019

Sep. 30, 2017

Sep. 22, 2021

Jan. 26, 2021

Dec. 22, 2020

Oct. 26, 2020

Mar. 31, 2020

Dec. 08, 2021

Oct. 21, 2021

Oct. 05, 2021

Jul. 01, 2021

Jun. 01, 2021

May 03, 2021

Feb. 20, 2021

Oct. 19, 2020

Sep. 01, 2020

Aug. 21, 2020

Dec. 31, 2019

Apr. 15, 2019

Jan. 04, 2019

Subsequent Events (Details) [Line Items]

Shares issued

1,750,000

Price per share (in Dollars per share)

$ 0.25

$ 0.1

$ 1.25

Price per share (in Dollars per share)

$ 1

$ 0.4

Shares of converted commitment unit

960,000

Shares issued

22,992,752

21,857,218

Accrued salary (in Dollars)

Price per share (in Dollars per share)

$ 0.0001

$ 0.0001

Gross proceeds (in Dollars)

$ 315,200

Stock options issued

1,000,000

Exercise price (in Dollars per share)

$ 0.25

Warrant [Member]

Subsequent Events (Details) [Line Items]

Purchase of warrants

1,138,500

Common Stock [Member]

Subsequent Events (Details) [Line Items]

Price per share (in Dollars per share)

$ 0.0001

Private Placement [Member]

Subsequent Events (Details) [Line Items]

Shares issued

227,700

Price per share (in Dollars per share)

$ 1

Note Warrant [Member]

Subsequent Events (Details) [Line Items]

Shares issued

910,800

Forecast [Member]

Subsequent Events (Details) [Line Items]

Operating lease expense (in Dollars)

$ 1,964.74

Private offering description

On October 26, 2020, AVRA issued an aggregate 256,027 Units (“Units”) at a price of $1.00 per Unit in a private offering (the “Offering”) to four “accredited investors.” Each Unit consisted of (a) four shares of our common stock (“Shares”); (b) a three-year warrant to purchase five Shares at an exercise price of $0.40 per Share; and (c) a put option of their Membership Units in Avra Air LLC for one share of our common stock. As a result of the foregoing, the investors were issued an aggregate of 1,024,108 Shares, warrants to purchase 1,280,135 Shares and put options for 256,027 Shares. One of the accredited investors, per his original commitment, subsequently invested an additional $45,000 on May 3, 2021 in this same Unit funding thus receiving an additional 180,000 Shares, a warrant to purchase 225,000 Shares and a put option for 45,000 Shares.

Shares issued

1,615,000

Price per share (in Dollars per share)

$ 0.4

Shares of commitments

135,000

Units of commitment (in Dollars)

$ 135,000

$ 45,000

Promissory notes plus (in Dollars)

25,000

Accrued interest (in Dollars)

$ 1,027

Shares of converted commitment unit

26,027

Commitments received of remaining balance (in Dollars)

$ 63,973

Units funding

256,027

Shares issued

629,375

Accrued salary (in Dollars)

$ 161,500

Employee agreement description

October 1, 2021, the Company’s CEO, converted a total of $595,000 of accrued salary into 5,950,000 shares of common stock at a price of $0.10 per share and agreed to receive 450,000 shares of common stock for $45,000 of the remaining salary due for the three months ending December 31, 2021at a price of $0.10 per share.

Price per share (in Dollars per share)

$ 0.1

Stock options issued

1,500,000

Exercise price (in Dollars per share)

$ 0.25

Forecast [Member] | Warrant [Member]

Subsequent Events (Details) [Line Items]

Purchase of warrants

1,175,000

Forecast [Member] | Common Stock [Member]

Subsequent Events (Details) [Line Items]

Price per share (in Dollars per share)

$ 0.1

Excess stock shares issued

45,000

Shares issued

174,553

2,229,231

2,229,231

Price per share (in Dollars per share)

$ 0.52

$ 0.13

Forecast [Member] | Private Placement [Member]

Subsequent Events (Details) [Line Items]

Shares issued

235,000

Price per share (in Dollars per share)

$ 1

Director [Member] | Forecast [Member]

Subsequent Events (Details) [Line Items]

Stock options issued

50,000

Exercise price (in Dollars per share)

$ 0.25

Chief Executive Officer [Member]

Subsequent Events (Details) [Line Items]

Borrowings (in Dollars)

$ 11,500

$ 17,700

Investment (in Dollars)

$ 202,700

Notes issued (in Dollars)

202,700

Chief Executive Officer [Member] | Forecast [Member]

Subsequent Events (Details) [Line Items]

Promissory notes plus (in Dollars)

$ 50,000

Shares issued

384,615

Conversion of common stock shares

384,615

Accrued salary (in Dollars)

$ 50,000

Stock options issued

390,000

Exercise price (in Dollars per share)

$ 0.25

Investor [Member]

Subsequent Events (Details) [Line Items]

Investment (in Dollars)

$ 25,000

Investor [Member] | Forecast [Member]

Subsequent Events (Details) [Line Items]

Shares issued

940,000

Farhan Taghizadeh [Member] | Board of Directors [Member] | Forecast [Member]

Subsequent Events (Details) [Line Items]

Excess stock shares issued

33,000

Ettore Tomassetti [Member] | Board of Directors [Member]

Subsequent Events (Details) [Line Items]

Excess stock shares issued

10,000

Nikhil Shah [Member] | Board of Directors [Member]

Subsequent Events (Details) [Line Items]

Excess stock shares issued

160,000

Maria Carin Bruck [Member] | Board of Directors [Member] | Forecast [Member]

Subsequent Events (Details) [Line Items]

Excess stock shares issued

5,600

Robert Santangelo [Member] | Board of Directors [Member] | Forecast [Member]

Subsequent Events (Details) [Line Items]

Excess stock shares issued

3.889

Vipul Patel [Member] | Board of Directors [Member] | Forecast [Member]

Subsequent Events (Details) [Line Items]

Excess stock shares issued

19,445

Henry Gewanter [Member] | Board of Directors [Member] | Forecast [Member]

Subsequent Events (Details) [Line Items]

Excess stock shares issued

7,000

Jared Stammel [Member] | Board of Directors [Member] | Forecast [Member]

Subsequent Events (Details) [Line Items]

Excess stock shares issued

19,444

Robert Chanson [Member] | Board of Directors [Member] | Forecast [Member] | Subsequent Event [Member]

Subsequent Events (Details) [Line Items]

Excess stock shares issued

25,000

Six consultants [Member] | Forecast [Member]

Subsequent Events (Details) [Line Items]

Accrued consulting fees (in Dollars)

$ 251,500

Expenses (in Dollars)

$ 4,500

Six consultants [Member] | Forecast [Member] | Common Stock [Member]

Subsequent Events (Details) [Line Items]

Shares issued

2,515,000

Price per share (in Dollars per share)

$ 0.1

Farhan Taghizadeh [Member] | Forecast [Member]

Subsequent Events (Details) [Line Items]

Shares issued

25,000

Stock options issued

350,000

Exercise price (in Dollars per share)

$ 0.25